Aragen Life Sciences has announced plans to invest Rs 2,000 crore in its existing facility in Hyderabad, aiming for expansion and generating 1,500 new jobs. The expansion focuses on drug discovery, development, and manufacturing activities for the global life sciences industry. The announcement was made during Chief Minister Revanth Reddy’s meeting with Manni Kantipudi, CEO of Aragen Life Sciences, at the World Economic Forum summit in Davos.
Aragen serves as a research and development (R&D) and manufacturing partner for the global life sciences industry. With over two decades of expertise, they specialize in delivering comprehensive contract research, development, and manufacturing services throughout the drug development process.
Their focus lies in the early-stage discovery and development of new molecular entities (NMEs), catering to diverse entities such as large pharmaceutical companies, biotech, agrochemical, and animal health firms. Whether it’s small or large molecules, Aragen offers global resources and proven capabilities at every stage of the biopharmaceutical lifecycle.
The expansion plans of Aragen Life Sciences reflects its vision to further invest in Hyderabad, contributing Rs 2,000 crore over the next five years. The investment by Aragen Life Sciences aligns with the government’s strategy to create a conducive environment for pharma companies, promoting innovation, and leveraging the rich talent pool in Hyderabad. The expansion will not only boost the local economy but also elevate the city’s global standing in the life sciences sector.
Hyderabad, known for its proactive approach in attracting investments, particularly in the life sciences domain, has been successful in fostering a thriving ecosystem for pharmaceutical research and development. The city’s status as a preferred location for CROs is further strengthened by Aragen’s substantial investment, reinforcing its pivotal role in advancing global drug discovery and development efforts.
Speaking after the meeting, Chief Minister Revanth Reddy expressed his delight, stating that he was pleased that Aragen Life Sciences, a global leader in pharma, had chosen massive investment plans in Hyderabad. He highlighted that this reflects the new government’s commitment to building a next-level vibrant ecosystem, extraordinary infrastructure, and showcasing a rich talent pool capable of driving innovation in the region.
Manni Kantipudi expressed excitement about their five-year expansion plans, revealing a decision to invest Rs 2,000 crore in Hyderabad, Telangana. He mentioned that Chief Minister Revanth Reddy’s leadership instills confidence in the belief that Hyderabad will solidify its recognized national status as the headquarters for CROs and CDMOs in the coming years.
This move strengthens Hyderabad’s position as a hub for Contract Research Organisations (CROs), serving over 1,000 global innovators in drug and device development. The Rs 2,000 crore investment by Aragen Life Sciences is expected to have a cascading effect on the local economy, creating employment opportunities, driving innovation, and attracting further investments in the life sciences sector.
The state government’s focus on building a robust ecosystem for pharmaceutical research aligns with the vision of making Hyderabad a global hub for life sciences and reinforces its commitment to the ‘Make in India’ initiative.
